145 related articles for article (PubMed ID: 25543274)
1. Antinuclear autoantibody profile in systemic sclerosis patients who are negative for anticentromere and anti-topoisomerase I specificities.
Caramaschi P; Tonolli E; Biasi D; Caimmi C; Pieropan S; Dal Forno I; Scambi C; Adami S
Joint Bone Spine; 2015 May; 82(3):209-10. PubMed ID: 25543274
[No Abstract] [Full Text] [Related]
2. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.
Shah AA; Rosen A; Hummers L; Wigley F; Casciola-Rosen L
Arthritis Rheum; 2010 Sep; 62(9):2787-95. PubMed ID: 20506513
[TBL] [Abstract][Full Text] [Related]
3. Immunoblotting on HEp-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis.
Tamby MC; Servettaz A; Guilpain P; Tamas N; Berezné A; Batteux F; Reinbolt J; Guillevin L; Weill B; Mouthon L
Clin Immunol; 2007 Apr; 123(1):82-8. PubMed ID: 17258939
[TBL] [Abstract][Full Text] [Related]
4. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis.
Bunn CC; Denton CP; Shi-Wen X; Knight C; Black CM
Br J Rheumatol; 1998 Jan; 37(1):15-20. PubMed ID: 9487245
[TBL] [Abstract][Full Text] [Related]
5. A case of systemic sclerosis with anticentromere, antitopoisomerase I, and anti-U1RNP antibodies.
Sato S; Ihn H; Soma Y; Shimozuma M; Shishiba T; Takehara K
J Rheumatol; 1993 Nov; 20(11):1961-3. PubMed ID: 8308786
[TBL] [Abstract][Full Text] [Related]
6. Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complex.
Kallenberg CG
Clin Rev Allergy; 1994; 12(3):221-35. PubMed ID: 7804956
[No Abstract] [Full Text] [Related]
7. CRI-EM is a human idiotype highly specific for scleroderma.
Vázquez-Abad D; Tian L; Monteón V; Zanetti M; Rothfield NF
Ann N Y Acad Sci; 1997 Apr; 815():512-5. PubMed ID: 9186713
[No Abstract] [Full Text] [Related]
8. Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma.
Ceribelli A; Cavazzana I; Franceschini F; Airò P; Tincani A; Cattaneo R; Pauley BA; Chan EK; Satoh M
J Rheumatol; 2010 Oct; 37(10):2071-5. PubMed ID: 20682663
[TBL] [Abstract][Full Text] [Related]
9. Late onset systemic sclerosis with seronegativity: a rare presentation of an uncommon disease.
Saxena D; Jain D; Yadav M; Giri K; Yadav T; Jain P
Reumatismo; 2019 Oct; 71(3):166-170. PubMed ID: 31649382
[TBL] [Abstract][Full Text] [Related]
10. Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?
Benyamine A; Bertin D; Heim X; Granel B; Bardin N
Eur J Intern Med; 2017 Oct; 44():e42-e44. PubMed ID: 28781194
[No Abstract] [Full Text] [Related]
11. Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis.
Hasegawa M; Hatta Y; Matsushita T; Hamaguchi Y; Fujimoto M; Takehara K
Mod Rheumatol; 2013 Sep; 23(5):913-9. PubMed ID: 22990335
[TBL] [Abstract][Full Text] [Related]
12. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
Hamaguchi Y
J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
[TBL] [Abstract][Full Text] [Related]
13. Antinuclear antibody in systemic sclerosis (scleroderma).
Okano Y
Rheum Dis Clin North Am; 1996 Nov; 22(4):709-35. PubMed ID: 8923592
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of patients with juvenile onset systemic sclerosis in an adult single-center cohort.
Foeldvari I; Nihtyanova SI; Wierk A; Denton CP
J Rheumatol; 2010 Nov; 37(11):2422-6. PubMed ID: 20843905
[TBL] [Abstract][Full Text] [Related]
15. Scleroderma subsets are best detected by the simultaneous analysis of the autoantibody profile using commercial ELISA.
Parodi A; Drosera M; Barbieri L; Rebora A
Dermatology; 2002; 204(1):29-32. PubMed ID: 11834846
[TBL] [Abstract][Full Text] [Related]
16. The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodies.
Hunzelmann N; Riemekasten G; Becker MO; Moinzadeh P; Kreuter A; Melchers I; Mueller-Ladner U; Meier F; Worm M; Lee H; Herrgott I; Pfeiffer C; Fierlbeck G; Henes J; Juche A; Zeidler G; Mensing H; Günther C; Sárdy M; Burkhardt H; Koehm M; Kuhr K; Krieg T; Sunderkötter C
Br J Dermatol; 2016 Jun; 174(6):1384-7. PubMed ID: 26708835
[No Abstract] [Full Text] [Related]
17. Analysis of ATP8B4 F436L Missense Variant in a Large Systemic Sclerosis Cohort.
López-Isac E; Bossini-Castillo L; Palma AB; Assassi S; Mayes MD; Simeón CP; Ortego-Centeno N; Vicente E; Tolosa C; Rubio-Rivas M; Román-Ivorra JA; Beretta L; Moroncini G; Hunzelmann N; Distler JHW; Riemekasten G; de Vries-Bouwstra J; Voskuyl AE; Radstake TRDJ; Herrick A; Denton CP; Fonseca C; Martín J
Arthritis Rheumatol; 2017 Jun; 69(6):1337-1338. PubMed ID: 28141915
[No Abstract] [Full Text] [Related]
18. Coexistence of serum anti-DNA topoisomerase I and anti-Sm antibodies: report of 3 cases.
Kameda H; Kuwana M; Hama N; Kaburaki J; Homma M
J Rheumatol; 1997 Feb; 24(2):400-3. PubMed ID: 9035005
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies in systemic sclerosis.
Vázquez-Abad D; Rothfield NF
Int Rev Immunol; 1995; 12(2-4):145-57. PubMed ID: 7650418
[TBL] [Abstract][Full Text] [Related]
20. Oral manifestations of Systemic Sclerosis and Correlation with anti-Topoisomerase I Antibodies (SCL-70).
Bajraktari IH; Kryeziu A; Sherifi F; Bajraktari H; Lahu A; Bajraktari G
Med Arch; 2015 Jun; 69(3):153-6. PubMed ID: 26261381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
